101
|
Randhawa V, Soltesz E, Wang Q, Wolski K, Tong M, Unai S, Buda T, Starling R, Tang W, Estep J. Unplanned HM3 Heart Failure-Related Hospitalizations: Reclassifying Post-Discharge Right Ventricular Failure. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
102
|
Martyn T, Faulkenberg K, Albert C, Il'Giovine Z, Montgomery R, Randhawa V, Yaranov D, Menon V, Estep J, Tang W, Starling R. Beneficial Acute Hemodynamic Effects of Sacubitril-Valsartan in Patients with Low-Cardiac Output Including Significant Improvement in PAPi. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.1239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
103
|
Randhawa V, Gabrovsek A, Soltesz E, Tong M, Unai S, Chen L, Mountis M, Estep J, Tang W, Hanna M. An Analysis of Our Ten-Year Cohort of Patients with Cardiac Amyloidosis Supported by the Continuous-Flow Left Ventricular Assist Device. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
104
|
Abratenko P, Alrashed M, An R, Anthony J, Asaadi J, Ashkenazi A, Balasubramanian S, Baller B, Barnes C, Barr G, Basque V, Berkman S, Bhanderi A, Bhat A, Bishai M, Blake A, Bolton T, Camilleri L, Caratelli D, Caro Terrazas I, Castillo Fernandez R, Cavanna F, Cerati G, Chen Y, Church E, Cianci D, Cohen E, Conrad J, Convery M, Cooper-Troendle L, Crespo-Anadón J, Del Tutto M, Devitt D, Domine L, Duffy K, Dytman S, Eberly B, Ereditato A, Escudero Sanchez L, Evans J, Fitzpatrick R, Fleming B, Foppiani N, Franco D, Furmanski A, Garcia-Gamez D, Gardiner S, Genty V, Goeldi D, Gollapinni S, Goodwin O, Gramellini E, Green P, Greenlee H, Gu L, Gu W, Guenette R, Guzowski P, Hamilton P, Hen O, Hill C, Horton-Smith G, Hourlier A, Huang EC, Itay R, James C, Jan de Vries J, Ji X, Jiang L, Jo J, Johnson R, Joshi J, Jwa YJ, Karagiorgi G, Ketchum W, Kirby B, Kirby M, Kobilarcik T, Kreslo I, LaZur R, Lepetic I, Li Y, Lister A, Littlejohn B, Lockwitz S, Lorca D, Louis W, Luethi M, Lundberg B, Luo X, Marchionni A, Marcocci S, Mariani C, Marshall J, Martin-Albo J, Martinez Caicedo D, Mason K, Mastbaum A, McConkey N, Meddage V, Mettler T, Miller K, Mills J, Mistry K, Mogan A, Mohayai T, Moon J, Mooney M, Moore C, Mousseau J, Murrells R, Naples D, Neely R, Nienaber P, Nowak J, Palamara O, Pandey V, Paolone V, Papadopoulou A, Papavassiliou V, Pate S, Paudel A, Pavlovic Z, Piasetzky E, Porzio D, Prince S, Pulliam G, Qian X, Raaf J, Radeka V, Rafique A, Ren L, Rochester L, Rogers H, Ross-Lonergan M, Rudolf von Rohr C, Russell B, Scanavini G, Schmitz D, Schukraft A, Seligman W, Shaevitz M, Sharankova R, Sinclair J, Smith A, Snider E, Soderberg M, Söldner-Rembold S, Soleti S, Spentzouris P, Spitz J, Stancari M, John JS, Strauss T, Sutton K, Sword-Fehlberg S, Szelc A, Tagg N, Tang W, Terao K, Thornton R, Toups M, Tsai YT, Tufanli S, Uchida M, Usher T, Van De Pontseele W, Van de Water R, Viren B, Weber M, Wei H, Wickremasinghe D, Williams Z, Wolbers S, Wongjirad T, Woodruff K, Wospakrik M, Wu W, Yang T, Yarbrough G, Yates L, Zeller G, Zennamo J, Zhang C. Search for heavy neutral leptons decaying into muon-pion pairs in the MicroBooNE detector. Int J Clin Exp Med 2020. [DOI: 10.1103/physrevd.101.052001] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
105
|
Petrova NL, Donaldson NK, Tang W, MacDonald A, Allen J, Lomas C, Leech N, Ainarkar S, Bevans J, Plassmann P, Kluwe B, Ring F, Whittam A, Rogers L, McMillan J, Simpson R, Donaldson ANA, Machin G, Edmonds ME. Infrared thermography and ulcer prevention in the high-risk diabetic foot: data from a single-blind multicentre controlled clinical trial. Diabet Med 2020; 37:95-104. [PMID: 31629373 DOI: 10.1111/dme.14152] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 10/14/2019] [Indexed: 11/28/2022]
Abstract
AIM To assess the usefulness of monthly thermography and standard foot care to reduce diabetic foot ulcer recurrence. METHODS People with diabetes (n = 110), neuropathy and history of ≥ 1 foot ulcer participated in a single-blind multicentre clinical trial. Feet were imaged with a novel thermal imaging device (Diabetic Foot Ulcer Prevention System). Participants were randomized to intervention (active thermography + standard foot care) or control (blinded thermography + standard foot care) and were followed up monthly until ulcer recurrence or for 12 months. Foot thermograms of participants from the intervention group were assessed for hot spots (areas with temperature ≥ 2.2°C higher than the corresponding contralateral site) and acted upon as per local standards. RESULTS After 12 months, 62% of participants were ulcer-free in the intervention group and 56% in the control group. The odds ratios of ulcer recurrence (intervention vs control) were 0.82 (95% CI 0.38, 1.8; P = 0.62) and 0.55 (95% CI 0.21, 1.4; P = 0.22) in univariate and multivariate logistic regression analyses, respectively. The hazard ratios for the time to ulcer recurrence (intervention vs control) were 0.84 (95% CI 0.45, 1.6; P = 0.58) and 0.67 (95% CI 0.34, 1.3; P = 0.24) in univariate and multivariate Cox regression analyses, respectively. CONCLUSIONS Monthly intervention with thermal imaging did not result in a significant reduction in ulcer recurrence rate or increased ulcer-free survival in this cohort at high risk of foot ulcers. This trial has, however, informed the design of a refined study with longer follow-up and group stratification, further aiming to assess the efficacy of thermography to reduce ulcer recurrence.
Collapse
|
106
|
Lee CF, Zhou K, Young WM, Wong CS, Ng TY, Lee SF, Leung K, Wong LKM, So KH, Tang W, Chong G, Chan SK, Yip YTE, Ma VYM, Yeung A, Chin CHY, Kwan MW, Tsang HT. Febrile neutropenia and its associated hospitalization in breast cancer patients on docetaxel-containing regimen: A retrospective cohort study on duration of prophylactic GCSF administration. Support Care Cancer 2019; 28:3801-3812. [PMID: 31832822 DOI: 10.1007/s00520-019-05111-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2019] [Accepted: 09/30/2019] [Indexed: 01/03/2023]
Abstract
PURPOSE To compare febrile neutropenia (FN) incidence and hospitalization among breast cancer patients on docetaxel with no granulocyte colony-stimulating factors (GCSF) primary prophylaxis (PP), 4/5-day PP, or 7-day PP. METHODS We identified 3916 breast cancer patients using docetaxel-cyclophosphamide (TC), doxorubicin-cyclophosphamide then docetaxel (AC-T), fluorouracil-epirubicin-cyclophosphamide then docetaxel (FEC-T), docetaxel-carboplatin-trastuzumab (TJH), or docetaxel-doxorubicin-cyclophosphamide (TAC) from a hospital pharmacy dispensing database in Hong Kong between 2014 and 2016. Patients were offered GCSF within 5 days since administering docetaxel. Outcomes included FN incidence, time to first hospitalization, hospitalization rate, and duration. RESULTS In TC regimen, FN incidence (with odds ratio, OR) of patients with no PP, 4/5-day PP, and 7-day PP was 21.69%, 7.95% (OR 0.31, p < 0.001), and 5.33% (OR 0.20, p < 0.001), respectively. In TJH regimen, FN incidence of patients with no PP, 4/5-day PP, and 7-day PP was 38.26%, 8.33% (OR 0.15, p < 0.001), and 8.57% (OR 0.15, p < 0.001), respectively. FN incidence of patients on AC-T regimen with no PP and 4/5-day PP was 20.93% and 6.84%, respectively (OR 0.28, p = 0.005); with FEC-T regimen, the incidence was 9.91% and 4.77%, respectively (OR 0.46, p = 0.035). Only 3.27% FN cases were not hospitalized. Mean (±standard deviation, SD) time to first hospitalization was 8.21 ± 2.44 days. Mean (±SD) duration of hospitalization for patients with no PP, 4/5-day PP, and 7-day PP was 4.66 ± 2.60, 4.37 ± 2.85, and 5.12 ± 2.97 days, respectively. CONCLUSION GCSF prophylaxis in breast cancer patients on docetaxel could reduce FN incidence and hospitalization. 4/5-day PP demonstrated similar efficacy to 7-day PP with superior saving benefits on healthcare expenditure.
Collapse
|
107
|
Shao T, Tang W, Li Y, Gao D, Lv K, He P, Song Y, Gao S, Liu M, Chen Y, Yi Z. Research on function and mechanisms of a novel small moleculeWG449E for hypertrophic scar. J Eur Acad Dermatol Venereol 2019; 34:608-618. [PMID: 31650631 DOI: 10.1111/jdv.16028] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Accepted: 09/04/2019] [Indexed: 11/29/2022]
|
108
|
Cao TH, Ling X, Chen C, Tang W, Hu DM, Yin GJ. Role of miR-214-5p in the migration and invasion of pancreatic cancer cells. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2019; 22:7214-7221. [PMID: 30468464 DOI: 10.26355/eurrev_201811_16255] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE To analyze the role of miR-214-5p in proliferation and metastasis of pancreatic cancer (PC) cells, as well as its underlying mechanism. PATIENTS AND METHODS 30 pairs of PC tissues and adjacent normal tissues were collected in our Department. The expression level of miR-214-5p was detected by quantitative Real-time-polymerase chain reaction (qRT-PCR). Biological information analysis and luciferase report gene assay were used to verify potential target genes of miR-214-5p. Cell counting kit-8 (CCK-8) and transwell methods were applied to observe the interference of miR-214-5p on invasion and migration of PC cells. Western blot (WB) assay was applied to determine the expression changes of Jagged 1 (JAG1) and epithelial-mesenchymal transition (EMT)-related genes in PC cells. RESULTS QRT-PCR results showed that the expression level of miR-214-5p is significantly down-regulated in PC tissues and cells. Bioinformatics software and luciferase report gene assay identified that JAG1 is a target gene of miR-214-5p. The negative correlation between protein expressions of miR-214-5p and JAG1 was assessed by Western Blot assay. Furthermore, miR-214-5p could suppress cell proliferation, invasion and migration, and it also blocked the EMT in PC cells in vitro. Meanwhile, JAG1 overexpression reversed the inhibitory effects of miR-214-5p on proliferation, invasion and migration of PC cells. CONCLUSIONS Overexpressing miR-214-5p could significantly inhibit malignant behavior of PC cells through targeted regulation of JAG1. Thus, miR-214-5p might be a potential therapeutic target for treatment of PC.
Collapse
|
109
|
Zhao W, Wang P, He W, Tao T, Li H, Li Y, Jiang W, Sun J, Ge X, Chen X, Zheng Y, Wei L, Chen C, Wang Y, Li C, Chen H, Yao B, Tang W, Zhu M. MYPT1 Down-regulation by Lipopolysaccharide-SIAH1/2 E3 Ligase-Ubiquitin-Proteasomal Degradation Contributes to Colonic Obstruction of Hirschsprung Disease. Cell Mol Gastroenterol Hepatol 2019; 9:345-347.e6. [PMID: 31759145 PMCID: PMC6997446 DOI: 10.1016/j.jcmgh.2019.11.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Revised: 11/10/2019] [Accepted: 11/12/2019] [Indexed: 12/13/2022]
Key Words
- anova, analysis of variance
- cir, circular
- d, dilated
- haec, hirschsprung-associated enterocolitis
- hd, hirschsprung disease
- long, longitudinal
- lps, lipopolysaccharide
- n, narrow
- rlc, regulatory light chain
- snp, sodium nitroprusside
Collapse
|
110
|
Li K, Guo Q, Zhang X, Dong X, Liu W, Zhang A, Li Y, Yan J, Jia G, Zheng Z, Tang W, Pan L, An M, Zhang B, Liu S, Fu B. Oral cancer-associated tertiary lymphoid structures: gene expression profile and prognostic value. Clin Exp Immunol 2019; 199:172-181. [PMID: 31652350 DOI: 10.1111/cei.13389] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/22/2019] [Indexed: 02/06/2023] Open
Abstract
Tertiary lymphoid structure (TLS) provides a local and critical microenvironment for both cellular and humoral immunity and supports effective antigen presentation and lymphocyte activation. However, the gene expression profile and prognostic significance of TLS in oral cancer remain largely unrevealed. In this study, we found the presence of both intratumoral and peritumoral TLSs in a series of 65 patients with oral cancer treated by surgical resection, with positive detection rates of 33.8 and 75.4%, respectively. The presence of intratumoral TLSs, but not peritumoral TLSs, was significantly associated with decreased P53 and Ki67 scores (P = 0·027 and 0·047, respectively). The survival analyses revealed that oral cancer patients with higher grades of TLSs was associated with improved disease-free survival (DFS) and overall survival (OS) (P = 0·037 and 0·031, respectively). Gene expression profiling analysis of the cytokines and chemokines responsible for lymph-node neogenesis identified a three-up-regulated-gene set, i.e. IL7, LTB and CXCL13, which was shown to be correlated with human oral cancer-associated TLSs. This study provides a framework for better understanding of oral cancer-associated TLSs and for delineating future innovative prognostic biomarkers and immune therapeutic strategies for oral cancer.
Collapse
|
111
|
Tang W. RACIAL DIFFERENCES IN NON-COGNITIVE SYMPTOMS IN ALZHEIMER’S DISEASE AND CAREGIVER DEPRESSION. Innov Aging 2019. [PMCID: PMC6845701 DOI: 10.1093/geroni/igz038.3150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Behavioral and psychological symptoms (BPS) represent a heterogeneous group of non-cognitive symptoms occurring in persons with Alzheimer’s disease (PwAD), and they are often associated with negative outcomes for AD caregivers. Evidence indicates differences in caregivers’ mental health across race/ethnic groups. However, there is a lack of research that compares racial differences in BPS in PwAD. This study aims to compare racial differences in BPS in PwAD and caregiver depression. The study analyzed data collected from the South Carolina AD Registry in 2010. The survey used in the interview included measures of caregiver depression, caregiver burden, PwAD’s non-cognitive symptoms, caregiving competence, caregiver distress, and demographics. The final analysis focused on 635 African-American (n=313) and white (n=322) caregivers. Mann-Whitney U-tests, Chi-square tests, and multiple linear regression were conducted. Among all PwAD, higher percentage of whites than African Americans exhibited apathy/indifference (67.52% vs 52.44%, p=.0001), depression/dysphoria (61.54% vs 44.59%, p<.0001), and anxiety (45.08% vs 29.64%, p<.0001). In terms of both frequency and severity of BPS, whites had significantly higher BPS score (Mean=35.49, SD=24.75) than African Americans (Mean=28.13, SD=23.97; p<.0001). Mean comparisons indicated significant group differences in caregiver depressive symptoms between white caregivers (mean=11.89, SD=6.90) and African-American caregivers (mean=9.41, SD=5.77). However, there were no racial differences in the relationship between BPS in PwAD and caregiver depression. The findings of this study highlight the importance of developing more effective and targeted treatment options and therapies for neuropsychiatric symptoms and delivering cultural relevant education programs/interventions to ethnic groups.
Collapse
|
112
|
Resciniti NV, Tang W, Tabassum M, Al-Hasan D, Lohman MC, Spencer M, Friedman D. A SCOPING REVIEW OF KNOWLEDGE EVALUATION INSTRUMENTS FOR FORMAL AND INFORMAL DEMENTIA CAREGIVER PROGRAMS. Innov Aging 2019. [PMCID: PMC6841595 DOI: 10.1093/geroni/igz038.2215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
With the increase in our older adult population there is a need for dementia training for informal and formal dementia caregivers. The objective of this scoping study was to assess dementia knowledge instruments utilized in educational programs and interventions intended for formal and informal dementia caregivers. Scoping review methodology was used to search PubMed, PsycInfo, CINAHL, and Web of Science with tailored database search terms. The search yielded 8,101 results, with 35 studies meeting inclusion criteria. Studies were conducted in eight countries, had varying study designs (RCTs=9, non-RCTs=6, one-group study design=20), and utilized previously published (19) and author-developed (16) instruments. Only two studies focused on minority populations. While author-developed instruments may be more relevant and time-saving, studies should strive to validate instruments or use previously published instruments to help standardize findings across studies and better understand the effects of education programs on caregiver knowledge.
Collapse
|
113
|
Gottfried M, de Marinis F, Tu H, Laktionov K, Feng J, Poltoratskiy A, Zhao J, Tan EH, Lee V, Kowalski D, Yang CT, Srinivasa B, Passaro A, Clementi L, Tang W, Huang DL, Cseh A, Park K, Zhou C, Wu YL. Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
114
|
Ji M, Tang W. Clinical significance and converionrate relevance of RAS genetic mutation analysis for unresectable colorectal liver metastases: A single-center retrospective study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz421.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
115
|
Passaro A, De Marinis F, Tu H, Laktionov K, Feng J, Poltoratskiy A, Zhao J, Tan EH, Gottfried M, Lee V, Kowalski D, Yang CT, Srinivasa B, Clementi L, Tang W, Huang DL, Cseh A, Park K, Zhou C, Wu YL. Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
116
|
Ageno W, Casella IB, Han CK, Schellong S, Schulman S, Singer DE, Desch M, Tang W, Voccia I, Zint K, Goldhaber SZ. P3849Baseline profile of patients treated for acute venous thromboembolism in routine clinical practice according to age and renal function in the RE-COVERY DVT/PE global cohort study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Observational studies provide the opportunity to evaluate routine practice without the selection and treatment criteria imposed in randomized clinical trials (RCTs).
Purpose
Using data from the RE-COVERY DVT/PE global observational study (enrolment January 2016 to May 2017), we describe the baseline profile of patients treated for acute venous thromboembolism (VTE) in routine clinical practice according to age and renal function.
Methods
Baseline patient characteristics, clinical features (comorbidities/medical history), and anticoagulant therapy were tabulated descriptively for the subgroups of age (<75, ≥75 years) and creatinine clearance (<30, 30 to <50 [moderate impairment], 50 to <80 [mild impairment], ≥80 mL/min). Anticoagulant therapy at baseline and at hospital discharge or 14 days after diagnosis (whichever was later) was recorded.
Results
In this observational study of 6122 patients with acute deep vein thrombosis, the proportions of patients at baseline who were ≥75 years of age (25.2%) or who had mild to moderate renal impairment (38.1%) were higher than in RCTs of non-vitamin K antagonist oral anticoagulants (NOACs) for acute VTE treatment (∼12–13% elderly and ∼26–29% with mild or moderate renal impairment) (from analyses of the RE-COVER trials; Hokusai-VTE and AMPLIFY). Older patients and those with renal impairment were more often female and were more likely to have comorbidities than the younger or normal renal function groups (Table). At the time of hospital discharge or 14 days after diagnosis, whichever was later, the majority was treated with NOACs (54%). Vitamin K antagonists were prescribed to approximately 1 in 5 patients. The use of NOACs decreased with worsening renal function, whereas the proportions treated with parenteral anticoagulation alone increased in the moderate renal impairment group compared with patients with normal renal function.
Conclusion
The population treated for acute VTE in routine clinical practice includes more elderly and renally impaired patients than represented in RCTs. These baseline data provide a snapshot of patient characteristics and patterns of anticoagulant therapy.
Acknowledgement/Funding
Funded by Boehringer Ingelheim
Collapse
|
117
|
Xu J, Liu T, Tang W, Chang W, Feng Q, Wei Y, Ren L, Ye Q, Cui Y, He G, Liu T, Zhu D, Ji M. Bevacizumab plus chemotherapy versus chemotherapy alone as first-line treatment for patients with RAS mutant unresectable colorectal liver-limited metastases: A single center randomized control trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.020] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
118
|
de Marinis F, Laktionov K, Poltoratskiy A, Egorova I, Hochmair M, Passaro A, Migliorino M, Metro G, Gottfried M, Tsoi D, Ostoros G, Rizzato S, Mukhametshina G, Schumacher M, Novello S, Tang W, Clementi L, Cseh A, Kowalski D. Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: Interim analysis of a phase IIIb, multi-national, open-label study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz259.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
119
|
de Marinis F, Tu H, Laktionov K, Feng J, Poltoratskiy A, Zhao J, Egorova I, Tan EH, Gottfried M, Lee V, Kowalski D, Yang CT, Srinivasa B, Passaro A, Clementi L, Tang W, Huang DCL, Cseh A, Zhou C, Wu YL. A combined analysis of two phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz259.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
120
|
Schellong S, Ageno W, Casella IB, Han CK, Schulman S, Singer DE, Desch M, Tang W, Voccia I, Zint K, Goldhaber SZ. P3848Baseline profile of patients treated for acute venous thromboembolism (VTE) in routine clinical practice according to VTE location in the RE-COVERY DVT/PE global cohort study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0688] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
In contrast to randomized clinical trials, observational studies provide the opportunity to evaluate routine practice in real-world patient populations.
Purpose
Using data from the RE-COVERY DVT/PE global observational study (enrollment January 2016 to May 2017), we have explored patient characteristics and anticoagulant treatment patterns in subgroups defined according to the type and location (proximal or distal lower limb) of acute venous thromboembolism (VTE).
Methods
Baseline patient characteristics, details of hospitalization and choice of anticoagulant therapy were tabulated descriptively for three groups of patients according to the type and location of their index VTE: pulmonary embolism (PE) (± any deep vein thrombosis; DVT); proximal (± distal) lower limb DVT, including the iliac vein; or distal lower limb DVT. Anticoagulant therapy at baseline and at hospital discharge or 14 days after diagnosis (whichever was later) was recorded.
Results
Of the 6122 eligible patients, 324 who had DVT at locations other than the lower limb and no PE were excluded from this analysis (as a key objective was to compare subgroups with DVT in the lower extremities according to whether the location was distal alone or involved the proximal segment). The remaining 5798 patients had either distal DVT (17.7%), proximal (± distal) DVT (40.0%) or PE (± any DVT) (42.3%) (Table). The likelihood of being diagnosed in an emergency department and of being hospitalized for VTE increased in line with the seriousness of the index event (distal DVT to PE). There were corresponding increases in age and the proportion of patients with comorbidities and/or medical history such as hypertension, diabetes mellitus or active cancer across these subgroups. At the time of hospital discharge or 14 days after diagnosis, whichever was later, non-vitamin K antagonist oral anticoagulants were the most commonly used anticoagulants (53% of patients in the PE group and 55–56% in the two DVT groups). The use of parenteral anticoagulant therapy alone appeared to be lower in the PE group than in the DVT groups, but the total use of parenteral therapy (alone or prior to oral anticoagulation) increased across groups from distal DVT (67%) to proximal DVT (74%) to PE (79%).
Conclusion
These data provide an insight into the potential differences in patient characteristics and treatment patterns among patients with PE, proximal/iliac lower limb DVT or distal lower limb DVT.
Acknowledgement/Funding
Funded by Boehringer Ingelheim
Collapse
|
121
|
De Marinis F, Laktionov K, Poltoratskiy A, Egorova I, Hochmair M, Passaro A, Migliorino M, Metro G, Gottfried M, Tsoi D, Ostoros G, Rizzato S, Mukhametshina G, Schumacher M, Novello S, Dziadziuszko R, Tang W, Clementi L, Cseh A, Kowalski D. P2.14-58 A Phase IIIb, Open-Label Study of Afatinib in Caucasian EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1843] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
122
|
Chen J, Zhang J, Su J, Gong Z, Chu X, Nie Q, Tang W, Song M, Zhong W. P2.14-36 Identification of Genomic Features in Tumor-Derived Organoids from Resectable NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
123
|
Liu T, Chang W, Ye W, He G, Ren L, Tang W, Chen J, Xu J. Detection of 5-hydroxymethylcytosine in circulating-free DNA for early diagnosis of colorectal cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz246.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
124
|
Xie P, Tang W, Li X, Dong Y, Sun X, Zhang J, Yu J. EGFR inhibitor versus chemotherapy as adjuvant treatment for locally-advanced EGFR-mutant non-small cell lung cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz259.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
125
|
Abratenko P, Adams C, Alrashed M, An R, Anthony J, Asaadi J, Ashkenazi A, Auger M, Balasubramanian S, Baller B, Barnes C, Barr G, Bass M, Bay F, Bhat A, Bhattacharya K, Bishai M, Blake A, Bolton T, Camilleri L, Caratelli D, Caro Terrazas I, Carr R, Castillo Fernandez R, Cavanna F, Cerati G, Chen Y, Church E, Cianci D, Cohen EO, Collin GH, Conrad JM, Convery M, Cooper-Troendle L, Crespo-Anadón JI, Del Tutto M, Devitt D, Diaz A, Domine L, Duffy K, Dytman S, Eberly B, Ereditato A, Escudero Sanchez L, Esquivel J, Evans JJ, Fitzpatrick RS, Fleming BT, Franco D, Furmanski AP, Garcia-Gamez D, Genty V, Goeldi D, Gollapinni S, Goodwin O, Gramellini E, Greenlee H, Grosso R, Gu L, Gu W, Guenette R, Guzowski P, Hackenburg A, Hamilton P, Hen O, Hill C, Horton-Smith GA, Hourlier A, Huang EC, James C, Jan de Vries J, Ji X, Jiang L, Johnson RA, Joshi J, Jostlein H, Jwa YJ, Karagiorgi G, Ketchum W, Kirby B, Kirby M, Kobilarcik T, Kreslo I, Lepetic I, Li Y, Lister A, Littlejohn BR, Lockwitz S, Lorca D, Louis WC, Luethi M, Lundberg B, Luo X, Marchionni A, Marcocci S, Mariani C, Marshall J, Martin-Albo J, Martinez Caicedo DA, Mason K, Mastbaum A, Meddage V, Mettler T, Mills J, Mistry K, Mogan A, Moon J, Mooney M, Moore CD, Mousseau J, Murphy M, Murrells R, Naples D, Nienaber P, Nowak J, Palamara O, Pandey V, Paolone V, Papadopoulou A, Papavassiliou V, Pate SF, Pavlovic Z, Piasetzky E, Porzio D, Pulliam G, Qian X, Raaf JL, Rafique A, Ren L, Rochester L, Rogers HE, Ross-Lonergan M, Rudolf von Rohr C, Russell B, Scanavini G, Schmitz DW, Schukraft A, Seligman W, Shaevitz MH, Sharankova R, Sinclair J, Smith A, Snider EL, Soderberg M, Söldner-Rembold S, Soleti SR, Spentzouris P, Spitz J, Stancari M, John JS, Strauss T, Sutton K, Sword-Fehlberg S, Szelc AM, Tagg N, Tang W, Terao K, Thomson M, Thornton RT, Toups M, Tsai YT, Tufanli S, Usher T, Van De Pontseele W, Van de Water RG, Viren B, Weber M, Wei H, Wickremasinghe DA, Wierman K, Williams Z, Wolbers S, Wongjirad T, Woodruff K, Wu W, Yang T, Yarbrough G, Yates LE, Zeller GP, Zennamo J, Zhang C. First Measurement of Inclusive Muon Neutrino Charged Current Differential Cross Sections on Argon at E_{ν}∼0.8 GeV with the MicroBooNE Detector. PHYSICAL REVIEW LETTERS 2019; 123:131801. [PMID: 31697542 DOI: 10.1103/physrevlett.123.131801] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/08/2019] [Revised: 08/06/2019] [Indexed: 06/10/2023]
Abstract
We report the first measurement of the double-differential and total muon neutrino charged current inclusive cross sections on argon at a mean neutrino energy of 0.8 GeV. Data were collected using the MicroBooNE liquid argon time projection chamber located in the Fermilab Booster neutrino beam and correspond to 1.6×10^{20} protons on target of exposure. The measured differential cross sections are presented as a function of muon momentum, using multiple Coulomb scattering as a momentum measurement technique, and the muon angle with respect to the beam direction. We compare the measured cross sections to multiple neutrino event generators and find better agreement with those containing more complete treatment of quasielastic scattering processes at low Q^{2}. The total flux integrated cross section is measured to be 0.693±0.010(stat)±0.165(syst)×10^{-38} cm^{2}.
Collapse
|